PfizerGan: What's it Worth? $158bn?
This article was originally published in Scrip
Executive Summary
The latest pharma mega-merger could well be under way as Pfizer Inc. and Allergan PLC have confirmed they are discussing their options. But what is Pfizer likely to have to pay? Analyst estimates indicate the deal could be worth up to $158bn.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.